Opinion: Stop blaming Biogen for putting profit at the expense of patients. Blame the systems that enabled it.

By STAT News
| January 18, 2023

Congress released damning results of an 18-month investigation into the FDA's approval of Biogen's Alzheimer's drug, Aduhelm. The systems that enabled Biogen's actions, however, went largely unscrutinized.

Full story

#1

Physicians are in short supply. They are costly. Is the APP the answer to the CMO's workforce and budget challenges? ...

Amid the hype and promise, a growing tension is becoming clear: the reality of what AI can deliver versus what it can't. ...